Friday, Feb. 26, 2016, 66 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $670.88 to $272,610,119.00.

Highlighted Stocks Traded by Insiders:

Psychemedics (PMD) - FREE Research Report

Connick Harry F Sr, who is Director at Psychemedics, bought 1,000 shares at $12.63 on Feb. 26, 2016. Following this transaction, the Director owned 40,662 shares meaning that the stake was boosted by 2.52% with the 1,000-share transaction.

The shares most recently traded at $12.80, up $0.17, or 1.3% since the insider transaction. Historical insider transactions for Psychemedics go as follows:

  • 4-Week # shares bought: 6,507
  • 4-Week # shares sold: 2,837
  • 12-Week # shares bought: 6,507
  • 12-Week # shares sold: 2,837
  • 24-Week # shares bought: 6,507
  • 24-Week # shares sold: 2,837

The average volume for Psychemedics has been 20,100 shares per day over the past 30 days. Psychemedics has a market cap of $68.5 million and is part of the health care sector and health services industry. Shares are up 26.53% year-to-date as of the close of trading on Friday.

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The stock currently has a dividend yield of 4.75%. The company has a P/E ratio of 33.3. Currently, there are no analysts who rate Psychemedics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PMD - FREE

TheStreet Quant Ratings

rates Psychemedics as a

hold

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, feeble growth in the company's earnings per share and deteriorating net income. Get the full

Psychemedics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Exponent (EXPO) - FREE Research Report

Corrigan Catherine, who is Group Vice President at Exponent, sold 2,000 shares at $46.89 on Feb. 26, 2016. Following this transaction, the Group Vice President owned 33,853 shares meaning that the stake was reduced by 5.58% with the 2,000-share transaction.

The shares most recently traded at $47.25, up $0.36, or 0.77% since the insider transaction. Historical insider transactions for Exponent go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares sold: 44,398

The average volume for Exponent has been 114,400 shares per day over the past 30 days. Exponent has a market cap of $1.2 billion and is part of the services sector and diversified services industry. Shares are down 5.77% year-to-date as of the close of trading on Friday.

Exponent, Inc., together with its subsidiaries, provides engineering and scientific consulting services worldwide. It operates in two segments, Engineering and Other Scientific; and Environmental and Health. The stock currently has a dividend yield of 1.53%. The company has a P/E ratio of 29.4. Currently, there are no analysts who rate Exponent a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EXPO - FREE

TheStreet Quant Ratings

rates Exponent as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in net income. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full

Exponent Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Hawkins (HWKN) - FREE Research Report

Jergenson Duane M, who is Director at Hawkins, bought 6,000 shares at $32.00 on Feb. 26, 2016. Following this transaction, the Director owned 30,115 shares meaning that the stake was boosted by 24.88% with the 6,000-share transaction.

The shares most recently traded at $31.05, down $0.95, or 3.06% since the insider transaction. Historical insider transactions for Hawkins go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 8,224
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 8,224
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 8,224

The average volume for Hawkins has been 23,900 shares per day over the past 30 days. Hawkins has a market cap of $324.4 million and is part of the basic materials sector and chemicals industry. Shares are down 13.03% year-to-date as of the close of trading on Friday.

Hawkins, Inc. blends, manufactures, and distributes various chemical products. The company operates in two segments, Industrial and Water Treatment. The stock currently has a dividend yield of 2.61%. The company has a P/E ratio of 18.9. Currently, there are no analysts who rate Hawkins a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HWKN - FREE

TheStreet Quant Ratings

rates Hawkins as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Hawkins Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.